Biohaven

Biohaven

Biotechnology
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

$1.8B

Market Cap • 10/9/2026

2022

(4 years)

Founded

2022

(4 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

149,3

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,1

EPS

—

Market Cap

Market Cap

1,8B

EV

1,8B

EV/Revenue

0

EV/EBITDA

-3,3

EV/EBIT

-3,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-20,4%

Total Yield

-20,4%

Payout

0%

Retained Earnings

-2,4B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

-2,3%

Capex/OCF

0%

SBC/OCF

—

% PPE

4,1%

% Goodwill

0,4%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

4,7

Quick Ratio

4,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium